Says growth “broad-based” across geographies. Cites new product launches. Says pipeline is delivering “pretty significantly.” Sees opportunity for gross margin expansion. Says “well set up” for 2H23 and into 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott (NYSE: ABT) Stock Gains on Q2 Beat; Lifts 2023 Revenue Forecast
- Abbott reports Q2 worldwide Medical Devices sales up 13.5% on reported basis
- Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business
- Abbott sees FY23 organic sales growth in low double digits, consensus $39.65B
- Abbott FY23 adjusted EPS view $4.30-$4.50, consensus $4.40